Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia

Respiratory Care
Heather M ArnoldMarin H Kollef

Abstract

Adjunctive aerosolized antibiotics (AAA) have been recommended in the setting of Gram-negative ventilator-associated pneumonia (VAP), but little is known about their influence on clinical outcomes. To assess outcomes associated with AAA for the treatment of Pseudomonas aeruginosa (PA) and Acinetobacter baumannii (AB) VAP. A retrospective, single-center cohort study at Barnes-Jewish Hospital in St Louis, Missouri. Consecutive subjects treated for bronchoalveolar lavage-confirmed PA or AB VAP between January 1, 2004 and December 31, 2009 were enrolled. Records of subjects treated with AAA were compared to those who did not receive AAAs (NAAA). Ninety-three patients were evaluated (NAAA n = 74, AAA n = 19, inhaled colistin n = 9, inhaled tobramycin n = 10). Patients receiving AAA were significantly more likely to be infected with multidrug-resistant bacteria (52.6% vs 14.9%, P < .001) and had greater Acute Physiology and Chronic Health Evaluation II scores (21.4 ± 5.7 vs 17.5 ± 5.3, P = .004) compared to patients receiving NAAA. NAAA subjects experienced a shorter time from VAP onset to appropriate intravenous antibiotic initiation (0.5 ± 0.9 d vs 2.6 ± 5.4 d, P = .038), but length of intravenous therapy was similar between groups...Continue Reading

Citations

Mar 26, 2013·Current Opinion in Pulmonary Medicine·François BarbierLila Bouadma
Oct 16, 2013·Current Opinion in Infectious Diseases·Marin H KollefA Bruce Montgomery
Sep 29, 2012·Lung India : Official Organ of Indian Chest Society·Dheeraj GuptaUNKNOWN Pneumonia Guidelines Working Group
Mar 22, 2014·American Journal of Respiratory and Critical Care Medicine·Lucy B Palmer, Gerald C Smaldone
Nov 29, 2014·BMC Infectious Diseases·Bárbara Borgatta, Jordi Rello
Feb 26, 2016·Annals of Clinical Microbiology and Antimicrobials·Tuna DemirdalSalih Atakan Nemli
Oct 7, 2015·Intensive Care Medicine·José Garnacho-MonteroUNKNOWN European Society of Intensive Care Medicine
Mar 4, 2014·Expert Opinion on Pharmacotherapy·Adamantia LiapikouAntonio Torres
Oct 24, 2014·Future Microbiology·Garyphallia PoulakouGeorge Dimopoulos
Apr 19, 2015·Critical Care : the Official Journal of the Critical Care Forum·Fernando G ZampieriOtavio T Ranzani
Dec 7, 2016·Expert Review of Anti-infective Therapy·G PoulakouG Dimopoulos
Apr 17, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J RelloJ A Roberts
Aug 6, 2017·The Annals of Pharmacotherapy·G Christopher Wood, Joseph M Swanson
Jan 6, 2018·Future Microbiology·Bruna Kern DonamoreSílvia Dias de Oliveira
Mar 25, 2015·Antimicrobial Agents and Chemotherapy·Helio S SaderRonald N Jones
Dec 16, 2016·Clinical Microbiology Reviews·Darren WongBrad Spellberg
Mar 8, 2013·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D van DuinUNKNOWN AST Infectious Diseases Community of Practice
Jul 1, 2017·Microbial Genomics·Leila G CasellaLindsey N Shaw
Sep 12, 2017·Expert Review of Respiratory Medicine·Katherine L RobertsMarin H Kollef
Jul 26, 2017·Drugs·Garyphallia PoulakouGeorge Dimopoulos
Nov 18, 2018·Critical Care : the Official Journal of the Critical Care Forum·Feng XuHua-Hao Shen
Mar 19, 2015·Current Opinion in Pulmonary Medicine·Lucy B Palmer
Aug 31, 2016·Expert Review of Anti-infective Therapy·D LeoniJ Rello
May 27, 2016·Clinical Microbiology Reviews·Eric WenzlerLarry H Danziger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Diana F FlorescuA C Kalil
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Andrea L KwaVincent H Tam
The Journal of Antimicrobial Chemotherapy
Mical PaulLeonard Leibovici
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
W CouetO Mimoz
© 2022 Meta ULC. All rights reserved